Jeg fant fasiten her:
12 uker for safety
3 måneder til 5 år for efficacy
Estimated Enrollment: 49
Study Start Date: December 2012
Estimated Study Completion Date: December 2021
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Last Updated: February 10, 2017
Primary Outcome Measures:
Safety/Dose limiting toxicity [ Time Frame: 12 weeks ]
Patients are closely monitored during and after injection of Betalutin over a 12 week period. Thereafter, at certain intervals up to 5 years. Safety evaluations are vital signs, physical examination, hematology and serum biochemistry.
Adverse events and abnormal laboratory values will be graded for toxicity according to CTCAE version 4.
Secondary Outcome Measures:
Efficacy [ Time Frame: 3 months - 5 years ]
CT or PET/CT imaging will be used to quantify changes in lesions on baseline imaging, with responses classified according to revised response criteria for NHL (Cheson, 2007.)